Ontario residents will now have expedited access to new cancer medications under the Funding Accelerated for Specific Treatments (FAST) program, as announced by Sylvia Jones, Ontario’s deputy premier and health minister. The initiative, unveiled at the Princess Margaret Cancer Centre in Toronto, aims to shorten the time it takes for patients to receive crucial cancer treatments, with the goal of reducing delays and enhancing accessibility.
Through the FAST program, individuals will be able to swiftly access up to 10 priority cancer drugs annually, endorsed by Health Canada via the Project Orbis Pathway. Project Orbis, an international effort initiated by the United States, involves several countries, including Canada, Australia, Brazil, Switzerland, Singapore, the United Kingdom, and Israel.
Patients will have the opportunity to obtain approved medications while Canadian jurisdictions negotiate pricing before public funding is allocated. Jones emphasized the program’s focus on expediency while ensuring safety standards are maintained.
When asked about how this initiative aligns with broader strategies from the pan-Canadian Pharmaceutical Alliance to accelerate drug price negotiation timelines nationwide, Jones emphasized the significance of collaboration among all provinces. The project underscores the importance of timely access to vital treatments, starting with oncology, according to Bettina Hamelin, president and CEO of Innovative Medicines Canada, a pharmaceutical industry representative.
Dr. Bishal Gyawali, a medical oncologist and associate professor at Queen’s University, praised the initiative as a positive development but stressed the importance of verifying that early drug access indeed benefits patients. Gyawali highlighted the need to question why pharmaceutical companies are not reducing their prices in addition to government funding considerations.
Mina Tadrous, a drug policy researcher at the University of Toronto, suggested that incentivizing companies to introduce medications to the Canadian market sooner could further accelerate patient access to essential treatments.
